FDA warned www.thesafepills.org for selling unapproved, misbranded tapentadol opioid drugs to U.S. consumers online.
What happened
FDA reviewed the website www.thesafepills.org and found it offering tapentadol, an opioid, under names including Aspadol, Typendol, and Generic Nucynta to U.S. consumers. FDA said the products are unapproved new drugs and are misbranded because they lack adequate directions for use and are offered without a prescription. No inspection dates were stated.
What FDA found
The website offered tapentadol products that are new drugs without FDA-approved applications.
FD&C Act section 505(a) [21 U.S.C. § 355(a)]The website introduced these unapproved drugs into interstate commerce.
FD&C Act section 301(d) [21 U.S.C. § 331(d)]The drugs' labeling lacked adequate directions for use, so they were misbranded.
FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]The website offered prescription drugs for sale without a prescription, misbranding them.
FD&C Act section 503(b)(1) [21 U.S.C. § 353(b)(1)]Offering the drugs for sale caused misbranded drugs to enter interstate commerce.
FD&C Act section 301(a) [21 U.S.C. § 331(a)]Dispensing a prescription drug without a prescription left it misbranded while held for sale.
FD&C Act section 301(k) [21 U.S.C. § 331(k)]
What FDA wants
FDA requests that www.thesafepills.org stop offering any unapproved and misbranded drugs for sale to U.S. consumers. It asks for a written response within 15 working days describing corrective steps and preventing recurrence.
Who should pay attention
- online pharmacies and website operators selling to U.S. consumers
- U.S. consumers buying opioids online
- drug distributors or importers handling prescription opioids
This is a summary. Read the original letter on fda.gov.